Abstract
Checkpoint inhibitor therapies are members of a new, groundbreaking class of drugs that reinvigorate the immune system to directly attack tumors. A rare side effect of checkpoint inhibitor therapy is pneumonitis, which typically presents as an interstitial lung disease. In this case report, we present a patient in whom combination therapy with the PD-1 inhibitor pembrolizumab and the CTLA-4 inhibitor ipilimumab induced severe airflow obstruction. This is the first report that shows that checkpoint inhibitors may induce airflow limitation.
Original language | English (US) |
---|---|
Pages (from-to) | 49-52 |
Number of pages | 4 |
Journal | Journal of Immunotherapy and Precision Oncology |
Volume | 1 |
Issue number | 1 |
DOIs | |
State | Published - 2018 |
Keywords
- Bronchiolitis
- Ipilimumab
- Pembrolizumab
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Immunology
- Immunology and Allergy